Tenapanor provides 'compelling' symptom relief in phase IIb trial: 3 insights

Tenapanor provided adequate symptom relief to 63.2 percent of patients, according to a study presented at the American College of Gastroenterology's 2016 annual meeting, Oct. 14 to Oct. 19, 2017 in Las Vegas, Gastroenterology and Endoscopy News reports.

William Chey, MD, a professor at Ann Arbor-based University of Michigan presented the phase IIb results at the college's annual meeting.

Tenapanor works by inhibiting sodium-proton exchanger 3 cells. Researchers treated 356 patients to either a 5 mg, 10 mg or 50 mg, twice-daily dosage of tenapanor or a placebo for 12 weeks. The 50 mg dose showed the most consistent results. Researchers recently began a phase-III study using the 50 mg dose.

Here's what you should know.

1. Approximately 63.2 percent of tenapanor taking patients achieved relief, which was greater than the 39.3 percent who achieved adequate relief using a placebo.

2. Those taking tenapanor also reported greater reduction in constipation severity and a great reduction in IBS-C severity.

3. Patients on tenapanor were more satisfied with the treatment than the other patients.

Dr. Chey concluded that the phase-IIb study successfully showed that tenapanor does inhibit sodium-proton exchanger 3 cells and appropriately manages irritable bowel syndrome with constipation.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast